IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 9549917 B1

PDFFull Text
Date of Patent:
Jan. 24, 2017

Filed:

Aug. 16, 2012

Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases

Applicants:

Casey C. Mccomas, Phoenixville, PA (US);

Nigel J. Liverton, Harleysville, PA (US);

Joerg Habermann, Munich, DE;

Uwe Koch, Dortmund, DE;

Frank Narjes, Kullavik, SE;

Peng LI, Shanghai, CN;

Xuanjia Peng, Shanghai, CN;

Richard Soll, San Diego, CA (US);

Hao Wu, Shanghai, CN;

Anandan Palani, Bridgewater, NJ (US);

Xing Dai, Cranford, NJ (US);

Hong Liu, Hillsborough, NJ (US);

Shuwen He, Edison, NJ (US);

Zhong Lai, East Brunswick, NJ (US);

Qun Dang, Westfield, NJ (US);

Nicolas Zorn, Fanwood, NJ (US);

Inventors:

Casey C. McComas, Phoenixville, PA (US);

Nigel J. Liverton, Harleysville, PA (US);

Joerg Habermann, Munich, DE;

Uwe Koch, Dortmund, DE;

Frank Narjes, Kullavik, SE;

Peng Li, Shanghai, CN;

Xuanjia Peng, Shanghai, CN;

Richard Soll, San Diego, CA (US);

Hao Wu, Shanghai, CN;

Anandan Palani, Bridgewater, NJ (US);

Xing Dai, Cranford, NJ (US);

Hong Liu, Hillsborough, NJ (US);

Shuwen He, Edison, NJ (US);

Zhong Lai, East Brunswick, NJ (US);

Qun Dang, Westfield, NJ (US);

Nicolas Zorn, Fanwood, NJ (US);

Assignee:

Merck Sharp & Dohme Corp., Rahway, NJ (US);

Attorneys:

Alysia A. Finnegan

Gloria M. Fuentes

Primary Examiner:

Sun Jae Yoo

Int. Cl.
CPC ...
A61K 45/06 (2006.01); A61K 31/506 (2006.01); A61K 31/444 (2006.01); A61K 31/443 (2006.01); A61K 31/497 (2006.01); A61K 31/501 (2006.01); A61K 31/695 (2006.01); A61K 31/424 (2006.01); A61K 31/4245 (2006.01); A61K 31/4439 (2006.01); C07D 405/14 (2006.01); C07D 413/14 (2006.01); C07D 409/14 (2006.01); C07D 417/14 (2006.01); C07D 471/04 (2006.01); C07D 498/04 (2006.01); C07D 513/04 (2006.01); A61K 31/433 (2006.01); A61K 31/5365 (2006.01); A61K 31/5377 (2006.01); A61K 31/5383 (2006.01); C07F 7/10 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4245 (2013.01); A61K 31/433 (2013.01); A61K 31/444 (2013.01); A61K 31/4439 (2013.01); A61K 31/497 (2013.01); A61K 31/501 (2013.01); A61K 31/506 (2013.01); A61K 31/5365 (2013.01); A61K 31/5377 (2013.01); A61K 31/5383 (2013.01); A61K 31/695 (2013.01); A61K 45/06 (2013.01); C07D 405/14 (2013.01); C07D 409/14 (2013.01); C07D 413/14 (2013.01); C07D 417/14 (2013.01); C07D 471/04 (2013.01); C07D 498/04 (2013.01); C07D 513/04 (2013.01); C07F 7/10 (2013.01);
Abstract

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

Find Patent Forward Citations

Loading…